TY - JOUR
T1 - Temporal patterns of cancer burden in Asia, 1990–2019
T2 - a systematic examination for the Global Burden of Disease 2019 study
AU - GBD 2019 Asia and All Cancers Collaborators
AU - Sharma, Rajesh
AU - Abbastabar, Hedayat
AU - Abdulah, Deldar Morad
AU - Abidi, Hassan
AU - Abolhassani, Hassan
AU - Abrehdari-Tafreshi, Zahra
AU - Absalan, Abdorrahim
AU - Ali, Hiwa Abubaker
AU - Abu-Gharbieh, Eman
AU - Acuna, Juan Manuel
AU - Adib, Nasrin
AU - Sakilah Adnani, Qorinah Estiningtyas
AU - Aghaei, Abbas
AU - Ahmad, Aqeel
AU - Ahmad, Sajjad
AU - Ahmadi, Ali
AU - Ahmadi, Sepideh
AU - Ahmed, Luai A.
AU - Ajami, Marjan
AU - Al Hamad, Hanadi
AU - Al Hasan, Syed Mahfuz
AU - Alanezi, Fahad Mashhour
AU - Saeed Al-Gheethi, Adel Ali
AU - Al-Hanawi, Mohammed Khaled
AU - Ali, Abid
AU - Ali, Beriwan Abdulqadir
AU - Alimohamadi, Yousef
AU - Aljunid, Syed Mohamed
AU - Ali Al-Maweri, Sadeq Ali
AU - Alqahatni, Saleh A.
AU - AlQudah, Mohammad
AU - Al-Raddadi, Rajaa M.
AU - Al-Tammemi, Ala'a B.
AU - Ansari-Moghaddam, Alireza
AU - Anwar, Sumadi Lukman
AU - Anwer, Razique
AU - Aqeel, Muhammad
AU - Arabloo, Jalal
AU - Arab-Zozani, Morteza
AU - Ariffin, Hany
AU - Artaman, Al
AU - Arulappan, Judie
AU - Ashraf, Tahira
AU - Askari, Elaheh
AU - Athar, Mohammad
AU - Wahbi Atout, Maha Moh d.
AU - Azadnajafabad, Sina
AU - Badar, Muhammad
AU - Badiye, Ashish D.
AU - Elkord, Eyad
N1 - Publisher Copyright:
© 2023 The Author
PY - 2024/2
Y1 - 2024/2
N2 - Background: Cancers represent a challenging public health threat in Asia. This study examines the temporal patterns of incidence, mortality, disability and risk factors of 29 cancers in Asia in the last three decades. Methods: The age, sex and year-wise estimates of incidence, mortality, and disability-adjusted life years (DALYs) of 29 cancers for 49 Asian countries from 1990 through 2019 were generated as a part of the Global Burden of Disease, Injuries and Risk Factors 2019 study. Besides incidence, mortality and DALYs, we also examined the cancer burden measured in terms of DALYs and deaths attributable to risk factors, which had evidence of causation with different cancers. The development status of countries was measured using the socio-demographic index. Decomposition analysis was performed to gauge the change in cancer incidence between 1990 and 2019 due to population growth, aging and age-specific incidence rates. Findings: All cancers combined claimed an estimated 5.6 million [95% uncertainty interval, 5.1–6.0 million] lives in Asia with 9.4 million [8.6–10.2 million] incident cases and 144.7 million [132.7–156.5 million] DALYs in 2019. The age-standardized incidence rate (ASIR) of all cancers combined in Asia was 197.6/100,000 [181.0–214.4] in 2019, varying from 99.2/100,000 [76.1–126.0] in Bangladesh to 330.5/100,000 [298.5–365.8] in Cyprus. The age-standardized mortality rate (ASMR) was 120.6/100,000 [110.1–130.7] in 2019, varying 4-folds across countries from 71.0/100,000 [59.9–83.5] in Kuwait to 284.2/100,000 [229.2–352.3] in Mongolia. The age-standardized DALYs rate was 2970.5/100,000 [2722.6–3206.5] in 2019, varying from 1578.0/100,000 [1341.2–1847.0] in Kuwait to 6574.4/100,000 [5141.7–8333.0] in Mongolia. Between 1990 and 2019, deaths due to 17 of the 29 cancers either doubled or more, and 20 of the 29 cancers underwent an increase of 150% or more in terms of new cases. Tracheal, bronchus, and lung cancer (both sexes), breast cancer (among females), colon and rectum cancer (both sexes), stomach cancer (both sexes) and prostate cancer (among males) were among top-5 cancers in most Asian countries in terms of ASIR and ASMR in 2019 and cancers of liver, stomach, hodgkin lymphoma and esophageal cancer posted the most significant decreases in age-standardized rates between 1990 and 2019. Among the modifiable risk factors, smoking, alcohol use, ambient particulate matter (PM) pollution and unsafe sex remained the dominant risk factors between 1990 and 2019. Cancer DALYs due to ambient PM pollution, high body mass index and fasting plasma glucose has increased most notably between 1990 and 2019. Interpretation: With growing incidence, cancer has become more significant public health threat in Asia, demanding urgent policy attention and guidance. Its heightened risk calls for increased cancer awareness, preventive measures, affordable early-stage detection, and cost-effective therapeutics in Asia. The current study can serve as a useful resource for policymakers and researchers in Asia for devising interventions for cancer management and control. Funding: The GBD study is funded by the Bill and Melinda Gates Foundation.
AB - Background: Cancers represent a challenging public health threat in Asia. This study examines the temporal patterns of incidence, mortality, disability and risk factors of 29 cancers in Asia in the last three decades. Methods: The age, sex and year-wise estimates of incidence, mortality, and disability-adjusted life years (DALYs) of 29 cancers for 49 Asian countries from 1990 through 2019 were generated as a part of the Global Burden of Disease, Injuries and Risk Factors 2019 study. Besides incidence, mortality and DALYs, we also examined the cancer burden measured in terms of DALYs and deaths attributable to risk factors, which had evidence of causation with different cancers. The development status of countries was measured using the socio-demographic index. Decomposition analysis was performed to gauge the change in cancer incidence between 1990 and 2019 due to population growth, aging and age-specific incidence rates. Findings: All cancers combined claimed an estimated 5.6 million [95% uncertainty interval, 5.1–6.0 million] lives in Asia with 9.4 million [8.6–10.2 million] incident cases and 144.7 million [132.7–156.5 million] DALYs in 2019. The age-standardized incidence rate (ASIR) of all cancers combined in Asia was 197.6/100,000 [181.0–214.4] in 2019, varying from 99.2/100,000 [76.1–126.0] in Bangladesh to 330.5/100,000 [298.5–365.8] in Cyprus. The age-standardized mortality rate (ASMR) was 120.6/100,000 [110.1–130.7] in 2019, varying 4-folds across countries from 71.0/100,000 [59.9–83.5] in Kuwait to 284.2/100,000 [229.2–352.3] in Mongolia. The age-standardized DALYs rate was 2970.5/100,000 [2722.6–3206.5] in 2019, varying from 1578.0/100,000 [1341.2–1847.0] in Kuwait to 6574.4/100,000 [5141.7–8333.0] in Mongolia. Between 1990 and 2019, deaths due to 17 of the 29 cancers either doubled or more, and 20 of the 29 cancers underwent an increase of 150% or more in terms of new cases. Tracheal, bronchus, and lung cancer (both sexes), breast cancer (among females), colon and rectum cancer (both sexes), stomach cancer (both sexes) and prostate cancer (among males) were among top-5 cancers in most Asian countries in terms of ASIR and ASMR in 2019 and cancers of liver, stomach, hodgkin lymphoma and esophageal cancer posted the most significant decreases in age-standardized rates between 1990 and 2019. Among the modifiable risk factors, smoking, alcohol use, ambient particulate matter (PM) pollution and unsafe sex remained the dominant risk factors between 1990 and 2019. Cancer DALYs due to ambient PM pollution, high body mass index and fasting plasma glucose has increased most notably between 1990 and 2019. Interpretation: With growing incidence, cancer has become more significant public health threat in Asia, demanding urgent policy attention and guidance. Its heightened risk calls for increased cancer awareness, preventive measures, affordable early-stage detection, and cost-effective therapeutics in Asia. The current study can serve as a useful resource for policymakers and researchers in Asia for devising interventions for cancer management and control. Funding: The GBD study is funded by the Bill and Melinda Gates Foundation.
KW - Asia
KW - Cancer burden
KW - Disability adjusted life years
KW - Global burden of disease
KW - Incidence
KW - Mortality
UR - http://www.scopus.com/inward/record.url?scp=85182411899&partnerID=8YFLogxK
U2 - 10.1016/j.lansea.2023.100333
DO - 10.1016/j.lansea.2023.100333
M3 - Article
AN - SCOPUS:85182411899
SN - 2772-3682
VL - 21
JO - The Lancet Regional Health - Southeast Asia
JF - The Lancet Regional Health - Southeast Asia
M1 - 100333
ER -